Preview Mode Links will not work in preview mode

 

Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show is a window into the latest innovations in digital health and the changing dynamic between doctors and patients.

Topics on the show include

  • the emergence of personalized medicine and breakthroughs in genomics
  • advances in biopharmaceuticals
  • age related diseases and aging in place
  • using big data from wearables and sensors
  • transparency in the medical marketplace
  • challenges for connected health entrepreneurs

The audience includes researchers, medical professionals, patient advocates, entrepreneurs, patients, caregivers, solution providers, students, journalists, and investors.

Aug 2, 2021

Alain Maiore is the Co-Founder and CEO of Mnemo Therapeutics and has a mission to change the future of cell therapy.  The Mnemo platform EnfiniT is an integrated drug discovery engine that combines T-cell engineering technologies with greater target identification to transform the body's immune response to overcome...


Aug 2, 2021

Alain Maiore is the Co-Founder and CEO of Mnemo Therapeutics and has a mission to change the future of cell therapy.  The Mnemo platform EnfiniT is an integrated drug discovery engine that combines T-cell engineering technologies with greater target identification to transform the body's immune response to overcome...


Apr 7, 2020

David Arthur, CEO, Salarius Pharmaceuticals explains the role of our epigenome and what happens when someone is suffering from an epigenetic illness such as Ewing's sarcoma.  A whole series of cancers can trace their cause back to the body misreading genes and that leads to dysregulation of genetic expression. With few...


Apr 7, 2020

David Arthur, CEO, Salarius Pharmaceuticals explains the role of our epigenome and what happens when someone is suffering from an epigenetic illness such as Ewing's sarcoma.  A whole series of cancers can trace their cause back to the body misreading genes and that leads to dysregulation of genetic expression. With few...


Feb 19, 2020

James Brown DVM, CEO, DURECT Corporation talks about how DURECT is advancing epigenetic therapies to treat alcoholic hepatitis and non-alcoholic steatohepatitis (NASH).  The company's lead asset, DUR-928 has demonstrated promising therapeutic potential treating patients with alcoholic hepatitis, a life-threatening acute...